The angiotensin (Ang) type 1 receptor (AT1R) promotes functional and structural integrity of the arterial wall to contribute to vascular homeostasis, but this receptor also promotes hypertension. In our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y 6 receptor (P2Y 6 R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice. In mice, deletion of P2Y 6 R attenuated Ang II-induced increase in blood pressure, vascular remodeling, oxidative stress, and endothelial dysfunction. AT1R and P2Y 6 R formed stable heterodimers, which enhanced G protein-dependent vascular hypertrophy but reduced b-arrestin-dependent AT1R internalization. Pharmacological disruption of AT1R-P2Y 6 R heterodimers by the P2Y 6 R antagonist MRS2578 suppressed Ang II-induced hypertension in mice. Furthermore, P2Y 6 R abundance increased with age in vascular smooth muscle cells. The increased abundance of P2Y 6 R converted AT1R-stimulated signaling in vascular smooth muscle cells from b-arrestin-dependent proliferation to G proteindependent hypertrophy. These results suggest that increased formation of AT1R-P2Y 6 R heterodimers with age may increase the likelihood of hypertension induced by Ang II.
INTRODUCTION
Hypertension is a major risk factor of various diseases including stroke, heart failure, vascular disease, and kidney disease. Angiotensin II (Ang II), which is produced by the renin-angiotensin system, primarily functions as a physiological regulator of blood pressure and cardiovascular homeostasis, but it also plays a major role in the pathogenesis of hypertension (1) . In the aorta, Ang II promotes hypertrophy of vascular smooth muscle cells, resulting in hypertension by increasing arterial wall thickness and vascular resistance, a process called vascular remodeling (2) . Additionally, Ang II induces physiological proliferation (a process called hyperplasia) of vascular smooth muscle cells. Pharmacological studies suggest that Ang II is involved in neointimal hyperplasia after vessel injury (2, 3) . Ang II has hyperplastic effects in the newborn and in the neointima, but not in adult vascular smooth muscle cells (4) . The responsiveness of the artery to Ang II depends on age in rats (5, 6) . However, how vascular smooth muscle cells determine the responsiveness to Ang II under different developmental and region-specific conditions is mostly unclear.
Ang II binds to two types of G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors (GPCRs) called angiotensin II type 1 receptor (AT1R) and AT2R (7) . Although both receptors are found in vascular smooth muscle cells, AT1R accounts for most cardiovascular effects of Ang II (8, 9) . AT1R is primarily coupled with heterotrimeric G q/11 protein to induce intracellular Ca 2+ mobilization through phospholipase C activation, and with G 12/13 protein to activate Rho-dependent signaling. After GPCR stimulation, b-arrestin (bArr) is recruited to the cell membrane and triggers GPCR internalization to attenuate G protein-dependent signaling. In addition to receptor desensitization, bArr itself can mediate G protein-independent signaling (10, 11) . Ang II activates various signaling molecules, including mitogen-activated protein kinases and Akt, through G protein-and bArrdependent pathways (12, 13) . Although biochemical studies demonstrate that GPCRs transmit signals as monomeric entries (14, 15) , many GPCRs probably exist as homo-and heterodimers in living cells (15) . Receptor dimerization modulates receptor properties, including maturation and plasma membrane trafficking of nascent receptors, ligand binding, G protein selectivity, downstream signaling, and internalization (16) . Heterodimerization between different GPCRs increases the diversity of signaling pathways activated by GPCRs and their regulation. AT1R heterodimerizes with various other GPCRs (17) (18) (19) (20) (21) (22) (23) , suggesting cross-regulation between angiotensin II and other signaling pathways. The fourth to sixth transmembrane domain is expected to participate in heterodimerization (24) , and the DRY ligandbinding motif of AT1R appears to be critical for functional activation of oligomerized AT1R signaling (25) .
Purinergic P2Y receptors are a family of GPCRs that respond to extracellular mononucleotides (26) . Eight different subtypes of P2Y receptors (P2Y 1 R, P2Y 2 R, P2Y 4 R, P2Y 6 R, P2Y 11 R, P2Y 12 R, P2Y 13 R, and P2Y 14 R) have been identified in mammals and show marked differences in ligand selectivity and specificity of G protein coupling (27) . After mechanical stress (28) or cellular injury (29) , mononucleotides released from nonsecretory tissues may signal in an autocrine or paracrine manner to regulate biological functions. Additionally, dinucleotide phosphates, such as Up 4 A and Ap n A, are ligands that activate vasoregulatory processes (30, 31) and may activate purinergic receptors (32) . Multiple P2Y receptor subtypes, including P2Y 6 R (33, 34) , are present in blood vessels. G q -coupled P2Y 6 R has strong ligand selectivity for UDP (uridine 5′-diphosphate) and shows a ubiquitous distribution in mammalian tissues. P2Y 6 R activation induces a Ca 2+ response in vascular smooth muscle cells that results in contraction of isolated blood vessels (26) . These pharmacological studies suggest that P2Y 6 R plays an important role in cardiovascular function. Although P2Y 6 R knockout mice do not show abnormalities of the cardiovascular system under normal conditions (35) , P2Y 6 R ablation attenuates vascular inflammation in vivo under pathological conditions (36, 37) . These results suggest that P2Y 6 R participates in the development of pathological vascular remodeling.
We have previously shown that P2Y 6 R mediates pressure overloadinduced cardiac fibrosis in mice (38) . Mechanical stretch-induced nucleotides release initiates Rho-dependent fibrotic gene expressions in cardiomyocytes. Therefore, P2Y 6 R-G 12/13 signaling is speculated to act as an upstream mediator of Ang II-AT1R signaling to induce fibrosis. Here, we investigated whether P2Y 6 R contributes to Ang II-induced pathophysiological functions through functional coupling with AT1R.
RESULTS

P2Y 6 R deletion attenuates Ang II-induced vascular remodeling in mice
To investigate the contribution of P2Y 6 R in Ang II-induced chronic hypertension, we measured blood pressures of P2Y 6 ] mice infused with Ang II for 4 weeks. Mice of either genotype developed robust hypertension with Ang II treatment, but mean blood pressure of P2Y 6 R (−/−) mice was significantly lower than that of P2Y 6 R (+/+) mice (Fig. 1A) . Heart rate was similar in P2Y 6 R (+/+) and P2Y 6 R (−/−) mice (Fig. 1B) . Ang II treatment increased the medial cross-sectional area and wall-to-lumen ratio in both genotypes, but to a significantly lesser extent in P2Y 6 R (−/−) mice (Fig. 1 , C to E). Additionally, Ang II infusion significantly increased vascular fibrosis of P2Y 6 R (+/+) mice, which was markedly suppressed in P2Y 6 R (−/−) mice (Fig. 1F) . Generation of reactive oxygen species (ROS) is required for Ang II-induced vascular hypertrophy (13) , and 4-hydroxyl-2-nonenal (4-HNE) is a major membrane lipid peroxidation product and marker of oxidative stress (39) . We found that Ang II-induced accumulation of 4-HNE adducts in aortae was greatly suppressed in P2Y 6 R (−/−) mice compared with P2Y 6 R (+/+) mice (Fig. 1G ). These results suggest that deletion of P2Y 6 R in mice substantially protects tissues against the pathological effect of Ang II.
Ang II-induced vascular contraction is reduced in P2Y 6 R (−/−) mice
We next examined whether P2Y 6 R contributes to Ang II-induced vascular dysfunction using isolated abdominal aortic rings. We first confirmed the effect of long-term Ang II treatment on endothelium-dependent relaxation evoked by UDP, an endothelium-dependent relaxing factor (40) . UDP treatment induced vascular relaxation in a concentration-dependent manner, and the aortae from Ang II-infused mice showed inhibited UDP-evoked relaxation (Fig. 1H ). The aortae from P2Y 6 R (−/−) and P2Y 6 R (+/+) mice showed similar UDP-evoked relaxation, suggesting that UDP induced endothelialdependent relaxation through other P2Y receptors. Ang II pretreatment impaired UDP-induced relaxation to a lesser extent in P2Y 6 R (−/−) aortae than in P2Y 6 R (+/+) aortae (Fig. 1I) . Moreover, Ang II-but not norepinephrineinduced contraction was significantly lower in aortae from P2Y 6 R (−/−) mice compared with those from P2Y 6 R (+/+) mice (Fig. 1 , J and K), which suggested that AT1R-stimulated signaling was reduced in P2Y 6 R (−/−) mice.
P2Y 6 R participates in the Ang II-induced Ca 2+ response of vascular smooth muscle cells
Because Ang II-induced medial hypertrophy and contraction were impaired in blood vessels isolated from P2Y 6 R (−/−) mice (Fig. 1 , C and J), we next compared the AT1R response in isolated vascular smooth muscle cells. The intracellular Ca 2+ response induced by P2Y 6 R-specific agonist 3-phenacyl UDP (3-pUDP) was absent in vascular smooth muscle cells isolated from P2Y 6 R (−/−) mice ( Fig. 2A) . AT1R mRNA expression was not significantly different between P2Y 6 R (+/+) and P2Y 6 R (−/−) vascular smooth muscle cells (Fig. 2B) . However, the intracellular Ca 2+ response induced by Ang II was reduced in P2Y 6 R (−/−) cells (Fig. 2C) . Furthermore, retroviral expression of mouse P2Y 6 R-IRES (internal ribosomal entry site)-GFP (green fluorescent protein) into P2Y 6 R (−/−) cells led to a higher Ca 2+ response compared with GFP-expressing P2Y 6 R (−/−) cells (Fig. 2D ). These results suggested that P2Y 6 R promoted Ang II-induced G protein signaling in vascular smooth muscle cells.
P2Y 6 R heterodimerizes with AT1R
Heterodimerization modulates the function of several GPCRs (16) . To determine whether P2Y 6 R heterodimerizes with AT1R, we used a bioluminescence resonance energy transfer (BRET) assay in cells expressing different ratios of AT1R-Rluc (donor) and P2Y 6 R-YFP (yellow fluorescent protein) (acceptor) or YFP as a negative control. The BRET signal was saturated in cells expressing AT1R-Rluc and P2Y 6 R-YFP, but not in the AT1R-Rluc and YFP (Fig. 3A) . Moreover, overexpression of FLAG-P2Y 6 R as a competitor inhibited BRET signaling between AT1R-Rluc and P2Y 6 R-YFP in a concentration-dependent manner (Fig. 3B) . This finding suggested a specific interaction between P2Y 6 R and AT1R. Myc-P2Y 6 R coimmunoprecipitated with FLAG-AT1R in human embryonic kidney (HEK) 293 cells (Fig. 3C) . Moreover, endogenous P2Y 6 R coimmunoprecipitated with endogenous AT1R in rat aortae (Fig. 3D) , which suggested that these proteins formed a stable heterodimer.
P2Y 6 R binding prevents Ang II-induced desensitization of AT1R
bArr-dependent internalization of ligand-activated GPCR is important for receptor desensitization and turning off classical GPCR signaling (10, 11) . AT1R-YFP was mainly localized at the plasma membrane under basal conditions. After Ang II treatment, AT1R-YFP was localized to endosomes, which suggested that ligand-trigged receptor internalization had occurred (Fig. 3E) . Myc-P2Y 6 R was colocalized with AT1R-YFP at the plasma membrane under basal conditions. However, coexpression of P2Y 6 R partially inhibited internalization of AT1R in response to Ang II (Fig. 3, F and G). We used BRET to measure Ang II-triggered bArr recruitment to AT1R in HEK293 expressing AT1R-Rluc and bArr2-YFP. Ang II stimulation increased the BRET signal between AT1R-Rluc and bArr2-YFP. This response was reduced by overexpression of P2Y 6 R, which suggested that P2Y 6 R prevented Ang II-triggered bArr2 recruitment (Fig. 3H) . We then captured the transient interaction of bArr2 with AT1R by cross-linking immunoprecipitation. Ang II-induced coimmunoprecipitation of bArr2-YFP with FLAG-AT1R was mostly inhibited by myc-P2Y 6 R expression, suggesting that AT1R-P2Y 6 R heterodimerization inhibited ligand-triggered recruitment of bArr2 (Fig. 3I) . After bArr is recruited to activated GPCR, the GPCR-bArr complex is internalized. bArr2-YFP translocated from the cytosol to the intracellular puncta after Ang II treatment (Fig. 3J) , a response that was inhibited by expression of P2Y 6 R (Fig. 3K ).
We next tested whether endogenous P2Y 6 R participates in preventing desensitization of AT1R. Ang II-induced internalization of bArr2-YFP was greater in vascular smooth muscle cells from P2Y 6 R (−/−) mice than in those from P2Y 6 R (+/+) mice ( (a plasma membrane-localized fluorophore), was not altered in P2Y 6 R (+/+) vascular smooth muscle cells. In contrast, Ang II treatment significantly reduced the BRET signal in P2Y 6 R (−/−) vascular smooth muscle cells (Fig.  3N ), an effect that was significantly abolished by bArr2 knockdown (fig. S1). These results suggest that endogenous P2Y 6 R prevents bArr (mainly bArr2)-dependent desensitization of AT1R, resulting in enhanced G proteindependent signaling.
Disruption of the AT1R-P2Y 6 R heterodimer by MRS2578 inhibits Ang II-induced hypertension
We use the noncompetitive P2Y 6 R-selective antagonist MRS2578 to further test whether P2Y 6 R activity affected heterodimer formation (41) . MRS2578 impaired coimmunoprecipitation of myc-P2Y 6 R with FLAG-AT1R in a concentration-dependent manner in vascular smooth muscle cells (Fig. 4A) . The BRET signal between AT1R-Rluc and P2Y 6 R-YFP was also reduced by MRS2578, which suggested that MRS2578 binding to P2Y 6 R inhibited heterodimer formation of AT1R-P2Y 6 R (Fig. 4B ). Consistent with these results, MRS2578 promoted Ang II-induced internalization of AT1R in P2Y 6 R (+/+) vascular smooth muscle cells ( fig. S2A ). In contrast, the AT1R antagonist losartan did not affect AT1R-P2Y 6 R heterodimer formation ( fig. S2B ). UDP concentrations in plasma were unchanged in Ang IIinfused mice, and 3-pUDP binding had no effect on AT1R-P2Y 6 (4), we investigated whether age-dependent changes in P2Y 6 R abundance determine the response of vascular smooth muscle cells to Ang II. P2Y 6 R mRNA expression was higher in P30 vascular smooth muscle cells than in E17 or P1 vascular smooth muscle cells (Fig.  5A ). Consistent with this finding, ERK (extracellular signal-regulated kinase) activation induced by the P2Y 6 R-specific agonist 3-pUDP was greater in P30 vascular smooth muscle cells than in P1 vascular smooth muscle cells ( Fig. 5B and fig. S4 ). In contrast, although Ang II-triggered Akt activation was enhanced in P30 vascular smooth muscle cells (Fig. 5C ), Ang II-induced ERK activation was similar in vascular smooth muscle cells at different developmental stages (Fig. 5D ). G q inhibitory peptide blocked Ang II-induced Akt activation ( fig. S5 ), consistent with the involvement of G q a-mediated Ca 2+ mobilization in this process (12) . This finding suggested that G qmediated signaling was potentiated in P30 vascular smooth muscle cells. Ang II-stimulated AT1R activates not only G protein-dependent but also bArr-dependent signaling pathways (10, 11) . [Sar(1), Ile(4), Ile(8)]Ang II (S II), a biased AT1R agonist that selectively activates bArr-dependent pathways, did not activate Akt or ERK in P30 vascular smooth muscle cells (Fig.  5, E and F) . Knockdown of bArr1 and bArr2 had no effect on Ang II-induced Akt and ERK activation in P30 vascular smooth muscle cells ( fig. S6A ). However, S II induced activation of ERK, but not that of Akt, in E17 vascular smooth muscle cells (Fig. 5 , E and F), and ERK activation was partially suppressed by bArr1/2 knockdown ( fig. S6B ). These results suggested that bArr partially mediated Ang II-induced ERK activation in E17 neonatal vascular smooth muscle cells but that Ang II-induced Akt and ERK activation was G protein-dependent in P30 adult vascular smooth muscle cells.
We next examined the biological importance of G protein-and bArrdependent signals. Ang II treatment in P30, but not P1, vascular smooth muscle cells enhanced hypertrophic growth (Fig. 5G) as well as abundance of smooth muscle myosin heavy chain (SM-MHC), which encodes a marker of the mature contractile phenotype ( fig. S7) (42) . Activation of p70 ribosomal VSMCs were isolated from three mice). **P < 0.01.
S6 kinase (p70S6K), a major regulator of vascular hypertrophy (43) , was enhanced in P30 adult vascular smooth muscle cells (Fig. 5H) . Ang IIinduced increases in p70S6K activation and protein synthesis (as assessed by [
3 H]leucine incorporation) were significantly suppressed by inhibition of ERK (U0126) and Akt (MK-2206) in P30 vascular smooth muscle cells (Fig. 5, I and J). These results suggested that G protein-dependent hypertrophic signaling was enhanced in P30 vascular smooth muscle cells. Egr-1 and platelet-derived growth factor-B (PDGF-B) are involved in the proliferative response to Ang II (4, 44) . We found that Egr-1 induction by Ang II stimulation was enhanced in E17 neonatal vascular smooth muscle cells (Fig. 5K) . The Ang II-induced increases in the expression of Egr-1 and PDGF-B mRNA and DNA synthesis (as assessed by [ 3 H]thymidine incorporation) were significantly suppressed by U0126, but not by MK-2206 (Fig. 5, L to N) . These results suggested that bArr-dependent activation of ERK was required for proliferative responses to Ang II.
Finally, we examined whether age-dependent changes in P2Y 6 R abundance determine the balance of G protein-dependent hypertrophic and bArr-dependent proliferative responses by Ang II. Consistent with inhibition of the intracellular Ca 2+ response (Fig. 2C) , Ang II-induced increases in protein synthesis and cell size were significantly suppressed in P2Y 6 R (−/−) vascular smooth muscle cells (Fig. 6A and fig. S8 ). Ang II-induced activation of p70S6K was also reduced in aortae from P2Y 6 R (−/−) mice compared with those from P2Y 6 R (+/+) mice (Fig. 6B and fig. S9 ). Ang II induced an increase in DNA synthesis in smooth muscle cells (Fig. 6C) . S II-induced ERK activation was enhanced in P2Y 6 R (−/−) vascular smooth muscle cells ( fig. S10A ), suggesting that bArr-dependent proliferative signaling predominated in P2Y 6 R (−/−) vascular smooth muscle cells. However, the number of medial nuclei was unchanged in descending aortae from Ang II-infused P2Y 6 R (−/−) mice ( fig. S10B ). Therefore, proliferation of vascular smooth muscle cells in the aorta was strictly regulated in vivo. MRS2578 treatment inhibited Ang II-induced Akt activation and hypertrophic growth in P30 adult vascular smooth muscle cells (Fig. 6, D and E) , which suggested a requirement for AT1R-P2Y 6 R heterodimer formation in Ang II-induced vascular hypertrophy. In addition to the G q -dependent hypertrophic response, MRS2578 inhibited Ang II-induced activation of RhoA, which mediates Ga 12/13 -dependent procontractile signaling ( fig. S11 ). In contrast, P2Y 6 R overexpression in E17 neonatal vascular smooth muscle cells completely suppressed the Ang II-induced increases in PDGF-B mRNA expression and DNA synthesis (Fig. 6, F and G) . In addition, P2Y 6 R-overexpressed E17 cells showed increased hypertrophic signaling, including activation of p70S6K, Akt, and ERK (Fig. 6H) and enhanced basal protein synthesis (Fig. 6I) . Furthermore, P2Y 6 R mRNA was greater in the descending aorta of older mice compared with that of young adult mice (Fig. 6J) . These results support the idea that the increase in P2Y 6 R abundance that occurs with age converts AT1R-stimulated signaling in vascular smooth muscle cells from bArr-dependent proliferation to G protein-dependent hypertrophy (Fig. 6K) .
DISCUSSION
We found that P2Y 6 R promoted Ang II-triggered hypertrophic signals in vascular smooth muscle cells (Fig. 6) . Accordingly, P2Y 6 R deletion attenuated Ang II-induced hypertension and vascular remodeling in mice (Fig. 1) . Heterodimer formation between AT1R and P2Y 6 R played an important role in P2Y 6 R-mediated regulation of Ang II responses (Fig. 4) . Several GPCRs have been identified as the dimerization partners of AT1R (17) . Tissuespecific regulation of Ang II signaling may explain why AT1R can form a heterodimer with various GPCRs. The a 2C -adrenergic receptor-AT1R complex is involved in norepinephrine secretion in sympathetic neurons (22) , and the cannabinoid CB 1 R-AT1R complex acts in activated hepatic stellate cells (18) . The bradykinin B2R-AT1R heterodimer is abundant in omental vessels from preeclamptic women (45) and mesangial cells from hypertensive rats (46) . Our study showed that the AT1R-P2Y 6 R complex regulated Ang II-evoked vascular remodeling in the thoracic aorta and supports the notion that heterodimerization of AT1R may generate functional diversity of Ang II responses in different tissues and under different conditions. AT1R can associate with various GPCRs. Identification of the molecular mechanism of heterodimerization of AT1R and P2Y 6 R could lead to understanding of the mechanism underlying heterodimerization of GPCRs. In our study, the P2Y 6 R antagonist MRS2578 inhibited the interaction of both receptors (Fig. 4) , whereas the P2Y 6 R selective agonist 3-pUDP and the AT1R antagonist losartan did not affect this interaction ( fig. S2 ). These findings suggested that the MRS2578-induced conformational change of P2Y 6 R is critical for AT1R interaction. Future structural biological analysis focusing on the conformational change of P2Y 6 R induced by MRS2578 may help to understand the molecular basis of AT1R-P2Y 6 R heterodimerization.
Mass spectrometry analysis has shown that the concentration of Ang II in human plasma is about 20 pM in healthy subjects and about 70 pM in chronic kidney disease patients (47) . Although locally generated Ang II may increase local Ang II concentrations, which act on vascular smooth muscle cells, the Ang II concentrations that we used in this study, especially in vitro, would be too high. Therefore, an aberrant increase in plasma Ang II concentrations under pathophysiological conditions may be required to induce AT1R-mediated hypertensive signaling in vivo. An alternative possibility is the activation of AT1R by mechanical stress in an Ang II-independent manner (48). Thus, both chemical and physical stimulation may cooperatively activate AT1R-P2Y 6 R heterodimer to induce hypertension, although it is not known whether AT1R-P2Y 6 R heterodimer responds to mechanical stretch.
Ang II triggers hypertrophic and hyperplastic responses of vascular smooth muscle cells. In our study, Ang II induced bArr-dependent proliferative and G protein-dependent hypertrophic responses in neonatal and adult vascular smooth muscle cells, respectively (Fig. 5) . This finding is consistent with a previous report that Ang II stimulates PDGF-B abundance and promotes DNA synthesis in newborn, but not adult, vascular smooth muscle cells (4) . We found that the age-dependent changes in P2Y 6 R abundance determined the balance of hypertrophic and hyperplastic signaling induced by Ang II (Fig. 6 ). Increased P2Y 6 R abundance in adult vascular smooth muscle cells inhibited Ang II-induced recruitment of bArr to AT1R and receptor desensitization (Fig. 3) , suggesting preferential activation of G proteindependent signaling. G q protein-dependent activation of Akt mediated Ang II-induced hypertrophic signaling, whereas Ang II-induced ERK contributed to hypertrophic and proliferative signals (Fig. 5, J and N) . Our results suggested that these two G q effectors differentially regulated the Ang II-induced responses in vascular smooth muscle cells as follows. G proteindependent activation of ERK and Akt stimulated p70S6K, a major regulator of hypertrophic growth (43) , and bArr-dependent ERK increased expression of Egr-1 through Elk-1, a nuclear regulator of cell proliferation (44) . The proliferative phenotype of vascular smooth muscle cells during neointimal formation relies on the ERK/Elk-1/Egr-1 pathway (44). We found that bArrdependent ERK activation mediated the Ang II-induced Elk-1/Egr-1 axis in the nucleus (Fig. 5) . Our results are supported by a previous report that m-opioid receptor activation by morphine leads to cytosolic ERK activation through a G protein-dependent pathway, whereas etorphine induces nuclear ERK activation through a bArr-dependent manner (49) . Additionally, in cardiomyocytes, Ang II-evoked ERK activation through the bArr2-dependent pathway supports proliferation, whereas G protein-mediated ERK activity induces hypertrophy (50) .
In addition to developmentally induced changes in abundance, P2Y 6 R abundance is also increased in pathological conditions. Inflammation reportedly increases P2Y 6 R abundance in endothelial and epithelial cells (36, 51) . We have previously shown that pressure overload and constitutive and P2Y 6 R in VSMCs from E17, P1, or P30 rats (n = 3 biological replicates; VSMCs were isolated from 10 E17, 10 P1, and 3 P30 rats). **P < 0.01. (B) ERK activation of P1 and P30 VSMCs induced by 3-pUDP (n = 3 independent experiments; VSMCs were isolated from 10 P1 and 3 P30 rats). **P < 0.01. (C to F) ERK and Akt activation of E17, P1, or P30 VSMCs exposed to Ang II (C and D) or S II (E and F) (n = 3 independent experiments; VSMCs were isolated from 10 E17, 10 P1, and 3 P30 rats). *P < 0.05, **P < 0.01. (G) Hypertrophic growth of P1 and P30 VSMCs induced by Ang II (n = 3 independent experiments; VSMCs were isolated from 10 P1 and 3 P30 rats). **P < 0.01.
(H) p70S6K activation of E17 and P30 VSMCs exposed to Ang II (n = 3 independent experiments; VSMCs were isolated from 10 E17 and 3 P30 rats). **P < 0.01. (I and J) Effects of MK-2206 and U0126 on p70S6K activation (I) and [
3 H]leucine incorporation (J) in P30 VSMCs exposed to Ang II [n = 3 (I) or n = 4 (J) independent experiments; VSMCs were isolated from three P30 rats]. *P < 0.05, **P < 0.01. CPM, counts per minute. (K) Expression of Egr-1 mRNA in E17 and P30 VSMCs exposed to Ang II (n = 3 biological replicates; VSMCs were isolated from 10 E17 and 3 P30 rats). **P < 0.01. (L to N) Effects of MK-2206 and U0126 on mRNA expression of Egr-1 (L) and PDGF-B (M) and [ 3 H] thymidine incorporation (N) in E17 VSMCs exposed to Ang II (n = 3 biological replicates; VSMCs were isolated from 10 E17 rats). *P < 0.05, **P < 0.01. activation of Ga 13 increase P2Y 6 R abundance in mouse hearts (38) . We also found that P2Y 6 R abundance was increased in the descending aorta of older mice (Fig. 6J) . This evidence suggests that environmental risk factors, including inflammation, mechanical stress, and aging, raise the probability of hypertension through increases in P2Y 6 R abundance.
We also found that the P2Y 6 R-specific antagonist MRS2578 (41) disrupted the interaction of AT1R and P2Y 6 R (Fig. 4, A and B) , and infusion of MRS2578 reduced Ang II-induced hypertension and vascular hypertrophy in mice (Fig. 4, E and F) . This experimental evidence suggests that AT1R-P2Y 6 R heterodimerization could be a potential therapeutic target for hypertension. Although angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely used in the treatment of hypertension, they increase the risk for congenital anomalies in infants if women take these medicines during pregnancy (52) . Genetic mutations in genes encoding the renin-angiotensin system have been identified in patients who have renal tubular dysgenesis (53) . Additionally, mice lacking renin-angiotensin system genes have abnormal renal development (54), whereas P2Y 6 R knockout mice show normal kidney development (35) . Therefore, compounds that disrupt the AT1R-P2Y 6 R heterodimer might be attractive drug candidates to treat hypertension without triggering abnormalities in kidney development.
MATERIALS AND METHODS
Materials
Ang II was purchased from Peptide Institute. Paraformaldehyde (PFA) and 10% formalin neutral buffer solution were from Wako. Dihydroethidium (DHE), UDP, and MRS2578 were from Sigma. 3-pUDP (PSB 0474) was from Tocris. Fura-2 AM was from Dojindo. [ (#4370), anti-ERK, anti-phospho-p70S6K (#9204), and anti-p70S6K (Cell Signaling Technology).
Experimental animals
Animal care and handling were carried out according to guidelines approved by the Animal Care and Use Ethical Committee of Kyushu University and the ethic committees at the National Institute for Physiological Sciences. Rodents were housed in air-conditioned conventional rooms with time-controlled lighting system. P2Y 6 R (−/−) mice were backcrossed onto a C57BL/6 background to obtain P2Y 6 R heterozygotes [P2Y 6 R (+/−) ]. Six-to 8-week-old male mice were used for experiments. Briefly, rodents were anesthetized by an intraperitoneal injection of midazolam (4 mg/kg), medetomidine hydrochloride (0.3 mg/kg), and butorphanol (5 mg/kg). A mini-osmotic pump (ALZET) filled with vehicle [phosphate buffered saline (PBS)] or Ang II (2 mg/kg per day) was intraperitoneally implanted into mice, and Ang II or PBS was continuously administered for 4 weeks. For acute infusion, mice were anesthetized and then Ang II (10 mM, 30 ml) was injected into the jugular vein. After 10 min, thoracic aortae were isolated.
Measurement of blood pressure and heart rate Systolic blood pressure, diastolic blood pressure, MBP, and heart rate in the daytime (2:00 p.m. to 5:00 p.m.) were measured in conscious mice using a noninvasive computerized tail-cuff system (BP-98AW, Softron). An average of 10 consecutive measurements per mouse was taken.
Histological analysis
Mice were sacrificed by intraperitoneal injection of midazolam, medetomidine hydrochloride, and butorphanol. The descending thoracic aorta was carefully isolated and cleaned of any adhering connective tissue. Paraffinembedded specimens were stained with H&E. Digital images were obtained using ECLIPSE 80i (Nikon). The H&E-stained medial cross-sectional areas, wall-to-lumen ratio, and number of nuclei were measured by ImageJ software. Fibrotic tissues were stained using Picrosirius red staining. Specimens embedded in OCT (optimum cutting temperature) compound were used to analyze ROS formation. Aortae were stained with anti-4-HNE antibody. The 4-HNE adducts were detected with Alexa Fluor 546 anti-mouse immunoglobulin G antibody. Digital images were taken at ×60 magnification using confocal microscopy (FV10i, Olympus), and five regions were randomly selected for each specimen. The average intensity was analyzed using MetaMorph software (Molecular Devices).
Measurement of vascular contraction and endothelial-dependent relaxation
Isometric tension was measured as previously described (55) . To analyze endothelium-dependent relaxation, abdominal aortae were carefully isolated from P2Y 6 R (+/+) or P2Y 6 R (−/−) mice that were infused with or without Ang II. The aortic rings were precontracted with norepinephrine (1 mM), and endothelial function was determined by examining the degree of relaxation in response to UDP. To measure vascular contraction, aortic rings were contracted with 100 mM KCl before measurement of Ang II-induced vascular contraction. The magnitude of the response was shown as a percentage of the reference constriction in response to 100 mM KCl.
Measurement of UDP concentration in mouse plasma
The blood samples were centrifuged at 2000g for 5 min and subsequently at 9000g for 5 min to isolate plasma. Collected plasma was then mixed with phenol/chloroform/isoamyl alcohol (25:24:1, v/v, pH 7.9; Nacalai Tesque Inc.), and after brief vortex, samples were centrifuged for 2 hours at 4°C. The aqueous phase was collected and washed three times with diethyl ether. All samples were filtered by Ultrafree-MC (Amicon) before high-performance liquid chromatography (HPLC) analysis. The concentration of nucleotides in the serum was analyzed using an HPLC system (Jasco) with an octadecylsilyl column (4.6 × 150 mm; GL Sciences Inc.) as previously described (56) . The mobile phase consisted of 8 mM tetrabutylammonium hydrogen sulfate (TBAHS), 35 mM KH 2 PO 4 , 15% MeOH (pH 3.5; solvent A), and 8 mM TBAHS, 35 mM KH 2 PO 4 , 50% methanol (pH 2.8; solvent B). The mobile phase was developed at 0.8 ml/min from 0 to 15 min in 100% solvent A, and from 15 to 30 min in 50% solvent B. Absorbance at 260 nm was monitored online with an UV-2075 UV (ultraviolet) detector (Jasco).
Cell culture
Primary mouse vascular smooth muscle cells were isolated by the enzymatic dispersion method. Thoracic aortae from three 4-to 6-week-old mice were quickly isolated, and perivascular fat and adventitia were discarded. Vessels were cut into small pieces and then digested by collagenase II and elastase at 37°C for 1 hour. The isolated cells were plated in Dulbecco's modified Eagle's medium (DMEM)/F-12 containing 20% fetal bovine serum (FBS). Primary rat vascular smooth muscle cells were isolated from 10 E17, 10 P1, or 3 P30 rat thoracic aortae, and cultured in low-glucose DMEM containing 10% FBS. HEK293 cells were cultured in high-glucose DMEM containing 10% FBS. Plasmid DNA was transfected into HEK293 cells or smooth muscle cells using X-tremeGENE 9 (Roche) or ViaFect (Promega), respectively.
Infection of recombinant adenoviruses
Recombinant adenoviruses expressing G protein inhibitory peptide (Ga s ct, Ga i ct, Ga q ct, or p115RGS) were generated and amplified as previously described (57) . Vascular smooth muscle cells were infected with recombinant adenoviruses at a multiplicity of infection of 50 for 24 hours. Cells were then starved in serum-free medium and cultured for an additional 24 hours. Under these conditions, almost 80% of cells were GFP-positive.
Intracellular Ca 2+ imaging
Intracellular Ca 2+ was measured using Fura-2 as previously described (8) . For the P2Y 6 R rescue experiment, vascular smooth muscle cells from P2Y 6 R (−/−) mice were infected with retrovirus encoding IRES-GFP or P2Y 6 R-IRES-GFP, and images of Fura-2 fluorescence of GFP-positive cells were analyzed.
Immunoprecipitation
HEK293 cells transfected with myc-P2Y 6 R and FLAG-AT1R were lysed in lysis buffer A [20 mM Hepes (pH 7.4), 100 mM NaCl, 3 mM MgCl 2 , and 1% NP-40] containing protease inhibitor cocktail for 15 min at 4°C. Cleared lysates were immunoprecipitated with anti-FLAG M2 agarose beads (Sigma) for 2 hours. Agonist-induced interaction between FLAG-AT1R and bArr2-YFP was detected by cross-linking experiments. In brief, transfected HEK293 cells were treated with 100 nM Ang II for 10 min. After washing with PBS, cells were incubated with 2 mM dithiobis(succinimidyl propionate) (DSP) cross-linker for 30 min at room temperature. The crosslinking reaction was quenched by the addition of tris-HCl (pH 7.5) at a final concentration of 50 mM. After washing twice with PBS, cells were lysed and immunoprecipitated. For inhibitor treatment, transfected vascular smooth muscle cells were treated with indicated concentrations of MRS2578 for 30 min and then lysed.
Small interfering RNA transfection
Vascular smooth muscle cells were transfected with small interfering RNAs (siRNAs) (20 nM) using Lipofectamine RNAiMAX reagent (Life Technologies). The siRNA sequences used in this study are listed in table S1. The gene silencing of mouse bArr1, mouse bArr2, rat bArr1, or rat bArr2 mRNA were 86 ± 6%, 49 ± 3%, 86 ± 6%, or 75 ± 1%, respectively (n = 3 biological replicates). Silencing efficiency was assessed by quantitative real-time polymerase chain reaction (PCR).
RNA preparation and real-time PCR
Total RNA was purified from cultured cells using Qiagen RNeasy Mini Kit. Real-time PCR was performed using Power SYBR Green PCR Master Mix (Life Technologies) or QuantiTect Probe RT-PCR Kit (Qiagen) and TaqMan probes. TaqMan probe and primer sequences are listed in table S2. Expression was normalized to 18S ribosomal RNA or GAPDH as the internal control.
Immunofluorescence
Transfected HEK293 cells were seeded on poly-L-lysine-coated glassbottom dish and stimulated with 100 nM Ang II for 15 min. To assess hypertrophy, vascular smooth muscle cells were seeded on glass-bottom dish at 4 × 10 4 cells per dish and serum-starved for 48 hours. Cells were then stimulated with 100 nM Ang II for 1 to 3 days. After stimulation, cells were fixed with 4% PFA for 15 min and permeabilized with 0.2 saponin or 0.1% Triton X-100 for 5 min. After washing with PBS, cells were incubated with blocking buffer (10% FBS in PBS) for 1 hour. Cells were stained with primary antibodies for FLAG, myc, aSMA, or SM-MHC11 at 4°C overnight. After washing with PBS, cells were incubated with CF488-or CF594-conjugated secondary antibodies (Biotium) for 1 hour. After washing with PBS, cells were incubated with DAPI (4′,6-diamidino-2-phenylindole) and then imaged on a confocal microscope (FV10i, Olympus). Cell surface area was quantified from more than 30 cells at each condition using FV10-ASW software.
Western blotting
Serum-starved vascular smooth muscle cells were pretreated with 10 mM MRS2578, 5 mM MK-2206, or 5 mM U0126 for 30 min, then stimulated with 100 nM Ang II, 10 mM S II, or 1 mM 3-pUDP for 5 min, and then harvested with lysis buffer B (lysis buffer A with 50 mM NaF, 1 mM Na 3 VO 4 , and 20 mM b-glycerophosphate) containing protease inhibitor cocktail for 15 min at 4°C. Cleared lysates were mixed with sample buffer.
RhoA activation
Vascular smooth muscle cells were plated on six-well plates at 1.5 × 10 5 cells per well. After 24 hours, cells were starved in serum-free medium for another 24 hours. Cells were pretreated with 10 mM MRS2578 for 25 min and then stimulated with 100 nM Ang II for 5 min. RhoA activation was measured by G-LISA RhoA Activation Kit (Cytoskeleton) according to the manufacturer's protocol. 
Measurement of ROS
Vascular smooth muscle cells were plated on 35-mm glass-bottom dish at 1 × 10 5 cells per dish. ROS production was detected by loading DHE (10 mM) at 37°C for 10 min before Ang II administration. The DHE fluorescence was observed using FV10i confocal microscope at 543-nm excitation and 560-nm emission wavelength, and DHE fluorescence intensity was quantified using FV10-ASW software.
Bioluminescence resonance energy transfer
HEK293 cells or vascular smooth muscle cells were seeded on a 12-or 6-well plate, respectively, 24 hours before transfection. To analyze the interaction of AT1R and P2Y 6 R, BRET between AT1R-Rluc (donor) and P2Y 6 R-YFP (acceptor) was measured. For the BRET saturation assay, HEK293 cells were transfected with a constant amount of AT1R-Rluc with an increasing amount of P2Y 6 R-YFP or YFP as a negative control. For the BRET competition assay, HEK293 cells were transfected with a constant amount of AT1R-Rluc and P2Y 6 R-YFP with an increasing amount of FLAG-P2Y 6 R as a competitor. For the bArr recruitment assay, AT1R-Rluc was transfected alone or with bArr2-YFP. To evaluate colocalization of AT1R with membrane compartment markers, AT1R-Rluc was transfected alone or with Venus-PM (C-terminal peptide of K-Ras, plasma membrane). After 48 hours of transfection, cells were suspended in PBS containing CaCl 2 , MgCl 2 , and glucose, and were transferred to 96-well plates. Coelenterazine h (5 mM) and 100 nM Ang II were added 10 min before BRET measurement. Luminescence and fluorescence signals were detected using SpectraMax i3 (Molecular Devices). The BRET ratio was calculated by dividing the fluorescence signal (531/22 emission filter) by the luminescence signal (485/20 emission filters).
Statistical analysis
Results are represented as means ± SEM. All experiments were repeated at least three times. For a normal distribution, statistical significance was determined by unpaired t test for two-group comparison and by one-way analysis of variance with Tukey's post hoc test for comparison among three or more groups. For a nonnormal distribution, statistical significance was determined by the Mann-Whitney test for two-group comparison and by the Kruskal-Wallis test with Dunn's post hoc test for comparison among three or more groups. Significance was considered at P < 0.05.
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